Illinois Municipal Retirement Fund lessened its holdings in shares of TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 30.6% in the first quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 54,194 shares of the biopharmaceutical company's stock after selling 23,907 shares during the quarter. Illinois Municipal Retirement Fund's holdings in TG Therapeutics were worth $2,137,000 as of its most recent filing with the SEC.
Several other hedge funds have also recently bought and sold shares of the business. Arizona State Retirement System raised its stake in shares of TG Therapeutics by 0.9% during the fourth quarter. Arizona State Retirement System now owns 42,639 shares of the biopharmaceutical company's stock valued at $1,283,000 after purchasing an additional 364 shares during the period. Golden State Wealth Management LLC grew its holdings in TG Therapeutics by 100.0% during the 1st quarter. Golden State Wealth Management LLC now owns 866 shares of the biopharmaceutical company's stock valued at $34,000 after purchasing an additional 433 shares in the last quarter. Summit Investment Advisors Inc. increased its stake in TG Therapeutics by 3.3% during the 4th quarter. Summit Investment Advisors Inc. now owns 14,606 shares of the biopharmaceutical company's stock worth $440,000 after buying an additional 463 shares during the period. NBC Securities Inc. lifted its holdings in TG Therapeutics by 82,300.0% in the 1st quarter. NBC Securities Inc. now owns 824 shares of the biopharmaceutical company's stock worth $32,000 after buying an additional 823 shares in the last quarter. Finally, Redwood Investments LLC boosted its position in TG Therapeutics by 0.9% in the 4th quarter. Redwood Investments LLC now owns 94,554 shares of the biopharmaceutical company's stock valued at $2,846,000 after buying an additional 886 shares during the last quarter. Hedge funds and other institutional investors own 58.58% of the company's stock.
Insider Buying and Selling at TG Therapeutics
In related news, Director Yann Echelard sold 10,000 shares of the company's stock in a transaction on Friday, June 13th. The shares were sold at an average price of $36.94, for a total value of $369,400.00. Following the sale, the director directly owned 228,816 shares of the company's stock, valued at $8,452,463.04. This represents a 4.19% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 10.64% of the company's stock.
TG Therapeutics Stock Up 2.5%
Shares of TG Therapeutics stock traded up $0.91 during trading hours on Thursday, hitting $37.20. 681,323 shares of the company's stock traded hands, compared to its average volume of 2,903,892. TG Therapeutics, Inc. has a twelve month low of $16.65 and a twelve month high of $46.48. The company has a market cap of $5.91 billion, a PE ratio of 155.00 and a beta of 1.91. The company has a quick ratio of 3.04, a current ratio of 4.02 and a debt-to-equity ratio of 1.03. The stock has a 50 day simple moving average of $36.92 and a 200-day simple moving average of $35.06.
TG Therapeutics (NASDAQ:TGTX - Get Free Report) last issued its quarterly earnings results on Wednesday, May 7th. The biopharmaceutical company reported $0.03 EPS for the quarter, missing analysts' consensus estimates of $0.19 by ($0.16). TG Therapeutics had a net margin of 10.13% and a return on equity of 18.88%. The business had revenue of $120.86 million during the quarter, compared to analysts' expectations of $117.07 million. During the same period in the prior year, the company posted ($0.07) EPS. The company's revenue for the quarter was up 90.4% on a year-over-year basis. Equities research analysts anticipate that TG Therapeutics, Inc. will post 0.08 earnings per share for the current fiscal year.
TG Therapeutics Company Profile
(
Free Report)
TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.
See Also
Before you consider TG Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and TG Therapeutics wasn't on the list.
While TG Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
